Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Neurology Clinical Trials Market Outlook (2022 to 2032)

The global Neurology Clinical Trials Market was valued at around US$ 5.4 billion in 2021. With a projected CAGR of 6.3% for the next ten years, the market is likely to reach a valuation of nearly US$ 10.5 billion by the end of 2032. The neurology clinical trials market is expected to achieve an absolute dollar opportunity growth of US$ 4.8 billion over the forecasted period.

Attributes Details
Neurology Clinical Trials Market Size (2021A) US$ 5.4 billion
Neurology Clinical Trials Market Size (2022E) US$ 5.7 billion
Projected Market Value (2032F) US$ 10.5 billion
Global Market Growth Rate (2022 to 2032) 6.3% CAGR
Key Companies Profiled
  • IQVIA
  • Novartis
  • Covance
  • Medpace
  • Charles River Laboratories
  • GlaxoSmithKline
  • Aurora Healthcare
  • Biogen

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Neurology Clinical Trials from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Future Market Insights reveals that Interventional study design led the market for neurology clinical trials. Market revenue through interventional study design grew at 5.6% CAGR from 2017 to 2021. While Huntington’s disease maintained the top Indication in neurology, clinical trials with a growth rate of 5.2% from 2017 to 2021.

The market is likely to grow due to an increase in global neurological disorders. This will drive the market for government spending and collaboration from pharmaceutical companies for the collaboration of new drugs and medication.

According to Lancet medical journal, total disability life adjusted years (DALYs) from, non-communicable neurological disorders like stroke, Alzheimer’s disease, dementia, Parkinson’s disease, and headache disorders increased in India and contributed 82.8% in 2019. Neurological disorders like stroke contributed to the highest share of deaths in India followed by Alzheimer’s. Based on the study, changes in lifestyle habits were a substantial contributor to non-communicable diseases. For instance, high systolic blood pressure, air pollution, and dietary factor contributed to 55.3%, 42.2%, and 28.1% respectively strokes.

What are the key challenges in Neurology Clinical Trials Market?

The requirement for neurology clinical trials is soaring, but several pharmaceutical companies are leaving the market due to the high cost of clinical trials across therapeutic areas and the high failure rates of clinical trials. Based on the Tufts Center for the Study of Drug Development, CNS drugs take 18% more time to develop when compared to other drugs, and only 6% of drugs are finally approved out of clinical testing. These statistics are discouraging enough for pharmaceutical companies not to invest in neurological clinical trials.

In order to make the transition from Phase I to Phase II trial, companies require data packages to enhance upcoming investments. Few academic and market scientists refuse to share data resulting in a delay in clinical trials.

On the other hand, diagnosis of the central nervous system (CNS) is studied on the basis of symptoms, and signs, and the reasons are varied in different patients within existing diagnostic categories. This makes the identification of the problem difficult.

Moreover, animal models have not shown effective predictive validity and reproducibility. Animal models of CNS disorders are less understood and are not able to recreate the varied neurological human disorders on their model.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How early-advancements are eyeing for investments, as the industry continues to move in late-stage clinical trials?

With the rise in neurological diseases, such as Alzheimer’s disease and Huntington's disease neuroscience remains a key domain for the majority of investments due to the high societal and monetary burden. Pharma and medical device companies have joined hands to offer better understanding and improved treatment. Moreover, the unprecedented rise in neurological disorders has called for the government to support funding for neurology clinical trials.

Scientists at the University of Sheffield’s Neuroscience Institute and NIHR Sheffield Biomedical Research Centre received funding of US$ 61 Million from the government to bring suitable treatment options for motor neuron disease (MillionD). The funding is expected to change the clinical trials in the coming years.

The government of Australia invested US$ 21.8 Million for the treatment of varied neurological disorders. Around 10 research projects were earmarked in Australia for the treatment of Supranuclear palsy and attempts would be made to reduce fatigue in patients after a stroke. Furthermore, the Clinical Trials Activity Initiative by the Australian Government aims to provide US$ 750 Million over 10 years from 2022 to 23 to Australian researchers in order to increase clinical trials in the country.

Regional-Insights

How is the market for neurology clinical trials shaping up in Europe?

The total number of DALYs resulting from neurological disorders was 21 million in the European Union, in 2017 and 41.1 million in WHO European region. A substantial burden will likely catch the attention of neurological clinical trials in Europe.

Development in the healthcare system has extended life expectancy. An increase in the older population has also come up with the burden of non-communicable neurological diseases which is the main driver for spending in neurology clinical trials in Europe.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

The USA Neurology Clinical Trials Market Analysis

The market for neurology clinical trials in the USA is valued at USA$ 3.7 billion by 2032. Revenue through neurology clinical trials grew at 5.3% CAGR from 2017 to 2021. The USA contributes to a vast number of neurological patients which drives the need for expanding clinical trials. In 2020, 5.8 million Americans suffered from Alzheimer’s disease. This number is projected to triple to 14 million by 2060.

Companies like Biogen and IQVIA have continuously advanced in innovating new drugs and receiving FDA approvals for neurological disorders in America. Government agencies like the National Institute of Neurological Disorders and Stroke fund clinical trials and numerous research programs to reduce the burden of neurological disorders in the USA. The absolute dollar opportunity growth in the USA is expected to be at USA$ 1.8 billion during the forecasted period of 2022 to 2032.

United Kingdom Neurology Clinical Trials Market Analysis

The market for neurology clinical trials in the United Kingdom was valued at USA$ 226 million in 2021. With an absolute dollar opportunity of USA$ 254 million, the market in the country is projected to reach a valuation of USA$ 493 million by 2032. From 2022 to 2032, the market in the United Kingdom is projected to grow at a CAGR of 7.6%.

Japan Neurology Clinical Trials Market Analysis

In Japan, the neurology clinical trials market in Japan was held at USA$ 179 million in 2021. By 2032, the market in Japan is expected to reach a valuation of USA$ 338 million. Growing at a CAGR of 5.7% from 2022 to 2032, the market in the country is likely to gross an absolute dollar opportunity of USA$ 145 million.

South Korea Neurology Clinical Trials Market Analysis

The neurology clinical trials market in South Korea is expected to be valued at USA$ 192 million by 2032. With a CAGR of 5.9%, the market in South Korea is expected to gross an absolute dollar opportunity of USA$ 84 million during the forecast period.

Category-wise Insights

How has the market for neurology clinical trials influenced study design methods?

Interventional study design dominated the market for neurology clinical trials and accounted for a 5.6% CAGR from 2017 to 2021. It is expected to grow at a rate of 6.5% during the forecasted period. The interventional study design is preferable in most clinical trials due to its safety and cost-effectiveness and acceptability of the Intervention. Interventional study design assists in gauging the direct impact on treatments or prevention of neurological diseases.

Competitive Landscape

Health organizations and pharmaceutical companies are largely aiming at expanding their manufacturing facilities, investing in Research and Development (R&D), and inventing new drugs for the treatment of neurological disorders. The key companies operating in the neurology clinical trials market include Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora Healthcare, Biogen, and IQVIA.

Some of the recent developments by key providers of neurology clinical trials are as follows:

  • In June 2022, Novartis announced the publication of Nature Medicine of Zolgensma data. The data revealed that children with spinal muscular atrophy (SMA) treated with Zolgensma were able to retain age-appropriate motor skills such as sitting, standing, and walking independently.
  • In June 2022, Biogen joined hands with Alectos Therapeutics to develop and commercialize a small molecule therapy known as AL01811, as a possible treatment for Parkinson’s disease. The collaboration will benefit Alectos with US$ 77.5 and US$ 630 million for development and commercial payments respectively. Moreover, Biogen will conduct responsible for regulatory costs and manufacturing once the therapy is approved for clinical settings.
  • In June 2022, Scientists at Yale University discovered that a drug developed by Bristol Myers Squibb has the ability to repair the loss of neuronal nexus known as synapse which is the key contributor to cognitive decline. The study also stated that it has the ability to restore synaptic connections in Alzheimer’s mouse models. The drug also minimized the toxic build-up of tau protein present in the brain of animals.
  • In April 2022, Novartis announced long-term data of Phase 3 ASCLEPIOS I/II trials. The data exhibited the efficacy of Kesimpta and stated that treatment of four years will reduce the risk of three and six months of confirmed disability and fewer relapses.
  • In April 2022, FDA granted Novartis, a commercial license to manufacture Zolgensma, a multi-product gene therapy with a 170,000 square-foot facility at Durham, N.C. site to test and release Zolgensma.
  • In December 2021, Novartis paid UCB US$ 150 million to provide the development of drugs relating to two clinical-stage Parkinson’s diseases. With the partnership with UCB, Novartis aims to widen its neuroscience prospectus. Based on their terms of collaboration, both the company intended to co-developing and fund the drug and further share the costs of additional development of the drug.
  • In July 2021, GlaxoSmithKline and Alector collaborated for two clinical-stage progranulin-elevating monoclonal antibodies, AL001 and AL101 for neurodegenerative diseases such as dementia, Parkinson’s disease, and Alzheimer’s disease.

Similarly, recent developments related to companies involved in Neurology Clinical Trials have been tracked by the team at Future Market Insights, which is available in the full report.

Key Segments Covered in Neurology Clinical Trials Industry Survey

Neurology Clinical Trials Market by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Neurology Clinical Trials Market by Study Design:

  • Interventional
  • Observational
  • Expanded access

Neurology Clinical Trials Market by Indication:

  • Epilepsy
  • Parkinson’s Disease
  • Huntington’s Disease
  • Stroke
  • Traumatic brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle regeneration
  • Other Indications

Neurology Clinical Trials Market by Region:

  • North America Neurology Clinical Trials Market
  • Latin America Neurology Clinical Trials Market
  • Europe Neurology Clinical Trials Market
  • South Asia Neurology Clinical Trials Market
  • East Asia Neurology Clinical Trials Market
  • Oceania Neurology Clinical Trials Market
  • Middle East & Africa Neurology Clinical Trials Market

Frequently Asked Questions

How much is the global Neurology Clinical Trials market currently worth?

The global Neurology Clinical Trials market was valued at US$ 5.4 billion in 2021 and US$ 5.7 billion in 2022.

What is the Neurology Clinical Trials Market Forecast through 2032?

The Neurology Clinical Trials industry is set to witness a high growth rate of 5.4% over the forecast period and is valued at US$ 10.5 by 2032.

Which study design dominated the market of neurology clinical trials?

Interventional study design maintained its largest share by 5.6% CAGR in 2021 and is expected to grow at 6.5% CAGR during the forecasted period of 2022 to 2032.

Who are the key players shaping the neurology clinical trials?

Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora healthcare, Biogen and IQVIA are the key companies operating in Neurology Clinical Trials Market

Which Indication is driving the demand for neurology clinical trials?

Huntington’s disease dominates the market for neurology clinical trials with 5.2% CAGR during 2017 to 2021. Anticipated growth rate of Huntington’s disease is 6.0% during the forecasted period.

Who are the top 5 countries driving the highest sales of Neurology Clinical Trials?

The USA, The United Kingdom., China, Japan, and South Korea are expected to drive the most sales growth of neurology clinical trials

What is the USA market outlook for Neurology Clinical Trials?

The neurology clinical trials market in the USA is valued at US$ 3.7 billion in 2032 and is expected to achieve a growth rate of 6.6% during the forecasted year.

Table of Content

1. Executive Summary | Neurology Clinical Trials Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Investment Feasibility Matrix

    3.4. Regulatory Landscape

        3.4.1. By Key Regions

        3.4.2. By Key Countries

4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Phase

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Phase, 2017 to 2021

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase, 2022 to 2032

        5.3.1. Phase I

        5.3.2. Phase II

        5.3.3. Phase III

        5.3.4. Phase IV

    5.4. Y-o-Y Growth Trend Analysis By Phase, 2017 to 2021

    5.5. Absolute $ Opportunity Analysis By Phase, 2022 to 2032

6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Study Design

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Study Design, 2017 to 2021

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Study Design, 2022 to 2032

        6.3.1. Interventional

        6.3.2. Observational

        6.3.3. Expanded Access

    6.4. Y-o-Y Growth Trend Analysis By Study Design, 2017 to 2021

    6.5. Absolute $ Opportunity Analysis By Study Design, 2022 to 2032

7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2021

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2022 to 2032

        7.3.1. Epilepsy

        7.3.2. Parkinson's Disease (PD)

        7.3.3. Huntington's Disease

        7.3.4. Stroke

        7.3.5. Traumatic Brain Injury (TBI)

        7.3.6. Amyotrophic Lateral Sclerosis (ALS)

        7.3.7. Muscle regeneration

        7.3.8. Other Indications

    7.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2021

    7.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032

8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. East Asia

        8.3.5. South Asia

        8.3.6. Oceania

        8.3.7. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Phase

        9.2.3. By Study Design

        9.2.4. By Indication

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Phase

        9.3.3. By Study Design

        9.3.4. By Indication

    9.4. Key Takeaways

10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Argentina

            10.2.1.4. Rest of Latin America

        10.2.2. By Phase

        10.2.3. By Study Design

        10.2.4. By Indication

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Phase

        10.3.3. By Study Design

        10.3.4. By Indication

    10.4. Key Takeaways

11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. Italy

            11.2.1.3. France

            11.2.1.4. The United Kingdom

            11.2.1.5. Spain

            11.2.1.6. Russia

            11.2.1.7. BENELUX

            11.2.1.8. Rest of Europe

        11.2.2. By Phase

        11.2.3. By Study Design

        11.2.4. By Indication

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Phase

        11.3.3. By Study Design

        11.3.4. By Indication

    11.4. Key Takeaways

12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Phase

        12.2.3. By Study Design

        12.2.4. By Indication

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Phase

        12.3.3. By Study Design

        12.3.4. By Indication

    12.4. Key Takeaways

13. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Thailand

            13.2.1.3. Malaysia

            13.2.1.4. Indonesia

            13.2.1.5. Rest of South Asia

        13.2.2. By Phase

        13.2.3. By Study Design

        13.2.4. By Indication

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Phase

        13.3.3. By Study Design

        13.3.4. By Indication

    13.4. Key Takeaways

14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Phase

        14.2.3. By Study Design

        14.2.4. By Indication

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Phase

        14.3.3. By Study Design

        14.3.4. By Indication

    14.4. Key Takeaways

15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. Rest of MEA

        15.2.2. By Phase

        15.2.3. By Study Design

        15.2.4. By Indication

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Phase

        15.3.3. By Study Design

        15.3.4. By Indication

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. The USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2021

            16.1.2.1. By Phase

            16.1.2.2. By Study Design

            16.1.2.3. By Indication

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2021

            16.2.2.1. By Phase

            16.2.2.2. By Study Design

            16.2.2.3. By Indication

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2021

            16.3.2.1. By Phase

            16.3.2.2. By Study Design

            16.3.2.3. By Indication

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2021

            16.4.2.1. By Phase

            16.4.2.2. By Study Design

            16.4.2.3. By Indication

    16.5. Argentina

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2021

            16.5.2.1. By Phase

            16.5.2.2. By Study Design

            16.5.2.3. By Indication

    16.6. Germany

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2021

            16.6.2.1. By Phase

            16.6.2.2. By Study Design

            16.6.2.3. By Indication

    16.7. Italy

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2021

            16.7.2.1. By Phase

            16.7.2.2. By Study Design

            16.7.2.3. By Indication

    16.8. France

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2021

            16.8.2.1. By Phase

            16.8.2.2. By Study Design

            16.8.2.3. By Indication

    16.9. The United Kingdom

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2021

            16.9.2.1. By Phase

            16.9.2.2. By Study Design

            16.9.2.3. By Indication

    16.10. Spain

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2021

            16.10.2.1. By Phase

            16.10.2.2. By Study Design

            16.10.2.3. By Indication

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2021

            16.11.2.1. By Phase

            16.11.2.2. By Study Design

            16.11.2.3. By Indication

    16.12. BENELUX

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2021

            16.12.2.1. By Phase

            16.12.2.2. By Study Design

            16.12.2.3. By Indication

    16.13. China

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2021

            16.13.2.1. By Phase

            16.13.2.2. By Study Design

            16.13.2.3. By Indication

    16.14. Japan

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2021

            16.14.2.1. By Phase

            16.14.2.2. By Study Design

            16.14.2.3. By Indication

    16.15. South Korea

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2021

            16.15.2.1. By Phase

            16.15.2.2. By Study Design

            16.15.2.3. By Indication

    16.16. India

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2021

            16.16.2.1. By Phase

            16.16.2.2. By Study Design

            16.16.2.3. By Indication

    16.17. Thailand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2021

            16.17.2.1. By Phase

            16.17.2.2. By Study Design

            16.17.2.3. By Indication

    16.18. Malaysia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2021

            16.18.2.1. By Phase

            16.18.2.2. By Study Design

            16.18.2.3. By Indication

    16.19. Indonesia

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2021

            16.19.2.1. By Phase

            16.19.2.2. By Study Design

            16.19.2.3. By Indication

    16.20. Australia

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2021

            16.20.2.1. By Phase

            16.20.2.2. By Study Design

            16.20.2.3. By Indication

    16.21. New Zealand

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2021

            16.21.2.1. By Phase

            16.21.2.2. By Study Design

            16.21.2.3. By Indication

    16.22. GCC Countries

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2021

            16.22.2.1. By Phase

            16.22.2.2. By Study Design

            16.22.2.3. By Indication

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Phase

        17.3.3. By Study Design

        17.3.4. By Indication

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. IQVIA

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. Novartis

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Covance

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. Medpace

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. Charles River Laboratories

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. GlaxoSmithKline

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. Aurora Healthcare

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. Biogen

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032

Table 2: Global Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 3: Global Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 4: Global Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 6: North America Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 7: North America Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 8: North America Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 10: Latin America Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 11: Latin America Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 12: Latin America Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 14: Europe Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 15: Europe Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 16: Europe Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 17: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 18: East Asia Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 19: East Asia Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 20: East Asia Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 22: South Asia Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 23: South Asia Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 24: South Asia Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 26: Oceania Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 27: Oceania Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 28: Oceania Market Value (US$ Million) Forecast by Indication, 2017 to 2032

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032

Table 30: MEA Market Value (US$ Million) Forecast by Phase, 2017 to 2032

Table 31: MEA Market Value (US$ Million) Forecast by Study Design, 2017 to 2032

Table 32: MEA Market Value (US$ Million) Forecast by Indication, 2017 to 2032
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ million) by Phase, 2022 to 2032

Figure 2: Global Market Value (US$ million) by Study Design, 2022 to 2032

Figure 3: Global Market Value (US$ million) by Indication, 2022 to 2032

Figure 4: Global Market Value (US$ million) by Region, 2022 to 2032

Figure 5: Global Market Value (US$ million) Analysis by Region, 2017 to 2032

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032

Figure 8: Global Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 9: Global Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 10: Global Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 11: Global Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 12: Global Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 13: Global Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 14: Global Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 15: Global Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 16: Global Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 17: Global Market Attractiveness by Phase, 2022 to 2032

Figure 18: Global Market Attractiveness by Study Design, 2022 to 2032

Figure 19: Global Market Attractiveness by Indication, 2022 to 2032

Figure 20: Global Market Attractiveness by Region, 2022 to 2032

Figure 21: North America Market Value (US$ million) by Phase, 2022 to 2032

Figure 22: North America Market Value (US$ million) by Study Design, 2022 to 2032

Figure 23: North America Market Value (US$ million) by Indication, 2022 to 2032

Figure 24: North America Market Value (US$ million) by Country, 2022 to 2032

Figure 25: North America Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 28: North America Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 29: North America Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 30: North America Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 31: North America Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 32: North America Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 33: North America Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 34: North America Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 35: North America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 36: North America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 37: North America Market Attractiveness by Phase, 2022 to 2032

Figure 38: North America Market Attractiveness by Study Design, 2022 to 2032

Figure 39: North America Market Attractiveness by Indication, 2022 to 2032

Figure 40: North America Market Attractiveness by Country, 2022 to 2032

Figure 41: Latin America Market Value (US$ million) by Phase, 2022 to 2032

Figure 42: Latin America Market Value (US$ million) by Study Design, 2022 to 2032

Figure 43: Latin America Market Value (US$ million) by Indication, 2022 to 2032

Figure 44: Latin America Market Value (US$ million) by Country, 2022 to 2032

Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 48: Latin America Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 51: Latin America Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 54: Latin America Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 57: Latin America Market Attractiveness by Phase, 2022 to 2032

Figure 58: Latin America Market Attractiveness by Study Design, 2022 to 2032

Figure 59: Latin America Market Attractiveness by Indication, 2022 to 2032

Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032

Figure 61: Europe Market Value (US$ million) by Phase, 2022 to 2032

Figure 62: Europe Market Value (US$ million) by Study Design, 2022 to 2032

Figure 63: Europe Market Value (US$ million) by Indication, 2022 to 2032

Figure 64: Europe Market Value (US$ million) by Country, 2022 to 2032

Figure 65: Europe Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 68: Europe Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 69: Europe Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 71: Europe Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 72: Europe Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 74: Europe Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 75: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 77: Europe Market Attractiveness by Phase, 2022 to 2032

Figure 78: Europe Market Attractiveness by Study Design, 2022 to 2032

Figure 79: Europe Market Attractiveness by Indication, 2022 to 2032

Figure 80: Europe Market Attractiveness by Country, 2022 to 2032

Figure 81: East Asia Market Value (US$ million) by Phase, 2022 to 2032

Figure 82: East Asia Market Value (US$ million) by Study Design, 2022 to 2032

Figure 83: East Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 84: East Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 85: East Asia Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 88: East Asia Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 89: East Asia Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 91: East Asia Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 92: East Asia Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 94: East Asia Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 97: East Asia Market Attractiveness by Phase, 2022 to 2032

Figure 98: East Asia Market Attractiveness by Study Design, 2022 to 2032

Figure 99: East Asia Market Attractiveness by Indication, 2022 to 2032

Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032

Figure 101: South Asia Market Value (US$ million) by Phase, 2022 to 2032

Figure 102: South Asia Market Value (US$ million) by Study Design, 2022 to 2032

Figure 103: South Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 104: South Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 105: South Asia Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 108: South Asia Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 109: South Asia Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 111: South Asia Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 112: South Asia Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 114: South Asia Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 115: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 117: South Asia Market Attractiveness by Phase, 2022 to 2032

Figure 118: South Asia Market Attractiveness by Study Design, 2022 to 2032

Figure 119: South Asia Market Attractiveness by Indication, 2022 to 2032

Figure 120: South Asia Market Attractiveness by Country, 2022 to 2032

Figure 121: Oceania Market Value (US$ million) by Phase, 2022 to 2032

Figure 122: Oceania Market Value (US$ million) by Study Design, 2022 to 2032

Figure 123: Oceania Market Value (US$ million) by Indication, 2022 to 2032

Figure 124: Oceania Market Value (US$ million) by Country, 2022 to 2032

Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 128: Oceania Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 131: Oceania Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 134: Oceania Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 137: Oceania Market Attractiveness by Phase, 2022 to 2032

Figure 138: Oceania Market Attractiveness by Study Design, 2022 to 2032

Figure 139: Oceania Market Attractiveness by Indication, 2022 to 2032

Figure 140: Oceania Market Attractiveness by Country, 2022 to 2032

Figure 141: MEA Market Value (US$ million) by Phase, 2022 to 2032

Figure 142: MEA Market Value (US$ million) by Study Design, 2022 to 2032

Figure 143: MEA Market Value (US$ million) by Indication, 2022 to 2032

Figure 144: MEA Market Value (US$ million) by Country, 2022 to 2032

Figure 145: MEA Market Value (US$ million) Analysis by Country, 2017 to 2032

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 148: MEA Market Value (US$ million) Analysis by Phase, 2017 to 2032

Figure 149: MEA Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032

Figure 151: MEA Market Value (US$ million) Analysis by Study Design, 2017 to 2032

Figure 152: MEA Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032

Figure 154: MEA Market Value (US$ million) Analysis by Indication, 2017 to 2032

Figure 155: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 157: MEA Market Attractiveness by Phase, 2022 to 2032

Figure 158: MEA Market Attractiveness by Study Design, 2022 to 2032

Figure 159: MEA Market Attractiveness by Indication, 2022 to 2032

Figure 160: MEA Market Attractiveness by Country, 2022 to 2032

Recommendations

Healthcare

Neurovascular Device Market

Published : March 2024

Healthcare

Neurology Services Market

Published : July 2023

Healthcare

Neurology Digital Therapeutics Market

Published : December 2021

Explore Healthcare Insights

View Reports

Neurology Clinical Trials Market